Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy

Understanding the signaling differences that distinguish human HER2-amplified (HER2-positive (HER2+)) breast cancers from other breast cancer subtypes may help to identify protein drug targets for the specific treatment of HER2+ breast cancers. We performed two kinome-wide small interfering RNA (siR...

Descripción completa

Detalles Bibliográficos
Autores principales: Lapin, V, Shirdel, E A, Wei, X, Mason, J M, Jurisica, I, Mak, T W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275559/
https://www.ncbi.nlm.nih.gov/pubmed/25500906
http://dx.doi.org/10.1038/oncsis.2014.45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275559/
https://www.ncbi.nlm.nih.gov/pubmed/25500906
http://dx.doi.org/10.1038/oncsis.2014.45

Ejemplares similares